Bildkälla: Stockfoto

Cantargia: Nadunolimab Scheduled for Phase II/III trial in PDAC - Redeye

Redeye offers a comment on Cantargia’s decision to participate in the Precision Promise trial with nadunolimab.

Börsvärldens nyhetsbrev
ANNONSER